Regeneron (NASDAQ: REGN) signs $1.0 billion Sanofi pact for new antibodies

What happened

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said on October 1, 2026, it entered the Sixth Amendment with Sanofi. Under the amendment, Sanofi will make a $1.0 billion upfront payment.

The companies also agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies that target IL-13, IL-4, IL-4R and IL-4xIL-13. Global profits on sales of the New Licensed Products will be shared equally. Regeneron will be the lead development and lead regulatory party before applications for marketing approval.

Regeneron will remain the lead regulatory party for applications for marketing approval and further commercialization in the United States. Sanofi will be the lead regulatory party for applications for marketing approval and further commercialization outside the United States.

Regeneron can also opt in, asset by asset, to Sanofi's Phase 2/3 asset lunsekimig and another early development product after certain trials. If it exercises that option, it will reimburse Sanofi for certain development costs.

In the same filing, Regeneron said it and Sanofi entered a settlement agreement. Under it, Regeneron agreed to dismiss its lawsuit over information access and audit rights.

Key numbers

Metric	Latest	Change	Source
Upfront payment	$1.0 billion		SEC 8-K
Potential milestone payments	up to an additional $7.0 billion		SEC 8-K
New long-acting antibodies	4 antibodies		SEC 8-K
Expected acquired IPR&D charge	$22 million		SEC 8-K
Expected net income per diluted share impact	-$0.18		SEC 8-K

Read more: Regeneron Pharmaceuticals (REGN) stock analysis and investment case

Why it matters

OptimistFi's case is that Regeneron turns a concentrated set of approved biologics into durable free cash flow that funds research and development, buybacks and pipeline investment. This agreement is mixed for that case.

The $1.0 billion upfront payment is about 45 times the approximately $22 million pre-tax acquired in-process research and development charge Regeneron expects in third quarter 2026. That gives Regeneron immediate cash and shared economics if the antibodies succeed. But the filing says up to an additional $7.0 billion depends on development, regulatory and commercial milestones.

It also says development costs above a budget cap fall to Regeneron, subject to later recoupment. The separate settlement also means Regeneron agreed to dismiss a lawsuit tied to Dupixent information access and audit rights.

Browse: stock research on every company OptimistFi covers

What's next

Regeneron said the full Sixth Amendment will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026. That filing will also include Regeneron's final third-quarter 2026 results, which are still subject to closing procedures.

A filing that confirms the $1.0 billion payment and the expected charge would support the cash-flow case. Slippage on either would weaken it.

More from OptimistFi